What’s new

• Jagsonpal to acquire 85% of hospital distributor Aequitas for ₹20.8 cr cash
• Aequitas FY26 revenue of ₹53.31 cr adds ~18.6% to Jagsonpal's top line
• Deal funded from internal accruals; no regulatory approvals needed; close by July 15, 2026

Why it matters

The acquisition diversifies Jagsonpal from retail/OTC into institutional hospital distribution, a channel with higher volume and recurring revenue. For a debt-free company with 23% ROE, this is a capital-efficient bolt-on that immediately boosts revenue and opens access to hospital chains.

What we’re watching

• Integration of Aequitas and margin impact on Jagsonpal's profitability
• Whether Jagsonpal pursues further hospital-channel acquisitions
• Retention of Aequitas founders and continuity of operations

The full read

A clean deal. Jagsonpal is paying ₹20.8 crore in cash, with no debt, for 85% of hospital distributor Aequitas Healthcare—a business that generated ₹53.31 crore in FY26 revenue, roughly 18.6% of Jagsonpal's own. Founders retain 15% and remain. No regulatory approvals needed, no related-party complications. For a micro-cap trading at 34x earnings with 23% ROE, this is a capital-efficient bolt-on that diversifies revenue into institutional channels and instantly lifts the top line. The next test: integration and whether distribution margins hold up against core pharma margins.

Primary source: BSE · NSE